Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcumin and Coenzyme Q10 in Myelodysplastic Syndromes
NCT00247026Phase 2Withdrawn
- Sponsor
- Hadassah Medical Organization
- Start
- Apr 2007
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of curcumin and coenzyme q10 in myelodysplastic syndrome (MDS), sponsored by Hadassah Medical Organization. Primary endpoint: Major hematologic improvement in any lineage. Planned start Apr 2007; status: withdrawn.
02
Drugs
curcumincoenzyme q10
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00247026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00247026.